Economic evaluations on cardiovascular preventive interventions in Argentina

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 4, 2010, Pages 465-473

  Colantonio, Lisandro Damián ^a,b,c   Martí, Sebastián García ^a,b   Rubinstein, Adolfo Luis ^a,b  

^a INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

^b Southern Cone of America Center of Excellence for Cardiovascular Health (SACECH)   (Argentina)

^c Fogarty International Clinical Research Scholars and Fellows (FICRS F) Program   (Argentina)

Author keywords

Argentina; cardiovascular disease; cost effectiveness; economic evaluations; Latin America middle income countries; prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIURETIC AGENT; PACLITAXEL; RAMIPRIL; RAPAMYCIN; VASOACTIVE AGENT;

ARGENTINA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG ELUTING STENT; ECONOMIC EVALUATION; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH PROMOTION; HEART FAILURE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; POLYPHARMACY; PREVENTIVE HEALTH SERVICE; PRIMARY PREVENTION; RESOURCE ALLOCATION; REVIEW; SECONDARY PREVENTION; SODIUM RETENTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ARGENTINA; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; PREVENTIVE HEALTH SERVICES; TREATMENT OUTCOME;

EID: 77955799062     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.50     Document Type: Review

References (44)

1. The Global Burden of Disease: 2004 Update. World Health Organization, Geneva, Switzerland (2008).
2. Preventing Chronic Diseases: a Vital Investment. World Health Organization, Geneva, Switzerland (2005).
3. Mathers CD, Lopez A, Stein C, et al. Deaths and Disease Burden by Cause: Global Burden of Disease Estimates for 2001 by World Bank Country Groups. Working Paper Series N° 18 (Second Project on Disease Control Priorities in Developing Countries). World Health Organization; World Bank; and Fogarty International Center, US National Institutes of Health, MD, USA (2005).
4. Argentina: Indicadores Básicos 2008. Ministerio de Salud, Buenos Aires, Argentina (2008).
5. Rubinstein A, Colantonio L, Bardach A, et al. Estimación de la carga de las enfermedades cardiovasculares atribuible a factores de riesgo modificables en Argentina. Rev. Panam. Salud Publica 27(4), 237-245 (2010).
6. Strong K, Mathers C, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save? Lancet 366(9496), 1578-1582 (2005).
7. Prevención de las Enfermedades Cardiovasculares: Guía de Bolsillo Para la Estimación y el manejo del Riesgo Cardiovascular. World Health Organization, Geneva, Switzerland (2008).
8. Gaziano TA, Reddy KS, Paccaud F, Horton S, Chaturvedi V. Cardiovascular disease. In: Disease Control Priorities in Developing Countries. Jamison DT, Breman JG, Measham AR, et al. (Eds). Oxford University Press and The World Bank, Washington DC, USA (2006).
9. Rodgers A, Lawes CM, Gaziano T, Vos T. The growing burden of risk from high blood pressure, cholesterol, and bodyweight. In: Disease Control Priorities in Developing Countries. Jamison DT, Breman JG, Measham AR, et al. (Eds). Oxford University Press and The World Bank, Washington DC, USA (2006).
10. Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Total Cardiovascular Risk. World Health Organization, Geneva, Switzerland (2007).
11. Schwappach DL, Boluarte TA, Suhrcke M. The economics of primary prevention of cardiovascular disease -a systematic review of economic evaluations. Cost Eff. Resour. Alloc. 5, 5 (2007).
12. Beaglehole R, Ebrahim S, Reddy S, Voute J, Leeder S. Prevention of chronic diseases: a call to action. Lancet 370(9605), 2152-2157 (2007).
13. Gaziano TA, Galea G, Reddy KS. Scaling up interventions for chronic disease prevention: the evidence. Lancet 370(9603), 1939-1946 (2007).
14. Augustovski F, Iglesias C, Manca A, et al. Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacoeconomics 27(11), 919-929 (2009).
15. Drummond MF, Sculpher MJ, Torrance GW, OBrien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, NY, USA (2005).
16. Ferrante D, Levy D, Peruga A, Compton C, Romano E. The role of public policies in reducing smoking prevalence and deaths: the Argentina Tobacco Policy Simulation Model. Rev. Panam. Salud Publica 21(1), 37-49 (2007). (Pubitemid 46699084)
17. Vazquez-Prokopec GM, Spillmann C, Zaidenberg M, Kitron U, Gurtler RE. Cost-effectiveness of chagas disease vector control strategies in northwestern Argentina. PLoS Negl. Trop. Dis. 3(1), e363 (2009).
18. Wilson LS, Strosberg AM, Barrio K. Cost-effectiveness of Chagas disease interventions in Latin America and the Caribbean: Markov models. Am. J. Trop. Med. Hyg. 73(5), 901-910 (2005).
19. Machnicki G. Análisis Costo-Efectividad de Programas Para la Prevención de Enfermedades Coronarias: Revisión de Estrategias Metodológicas. Concurso Asociación de Economía de la Salud de Argentina, Buenos Aires, Argentina (2000).
20. Grines CL, Marsalese DL, Brodie B, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction. J. Am. Coll. Cardiol. 31(5), 967-972 (1998).
21. Botto F, Von Schulz Hausmann C, Cneo J, Herrera V, Ferrante D. Costo-eficacia del uso de ramipril en pacientes de alto riesgo vascular en la Argentina. Rev. Argent. Cardiol. 71(1), 16-22 (2003).
22. Ferrante D. Angioplastía Transluminal Coronaria con Stents Recubiertos. Instituto de Efectividad Clínica y Sanitaria, Documentos de Evaluación de Tecnologías Sanitarias Nro 1, Buenos Aires, Argentina (2003).
23. Ferrante D, Pichon Riviere A, Augustovski F. Evaluación Económica de Neseritide en la Insuficiencia Cardíaca Descompensada en Argentina. Instituto de Efectividad Clínica y Sanitaria, Documentos de Evaluación de Tecnologías Sanitarias Nro 4, Buenos Aires, Argentina (2005).
24. Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet 370(9604), 2044-2053 (2007).
25. Lim SS, Gaziano TA, Gakidou E, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 370(9604), 2054-2062 (2007).
26. Pichon Riviere A, Augustovski F, Bardach A, Colantonio L, Rubinstein A. Cost-effectiveness of smoking cessation interventions in seven Latin American countries (CS2). In: ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 2nd Latin America Conference. ISPOR, Rio de Janeiro, Brasil (2009).
27. Rodriguez AE, Maree A, Tarragona S, et al. Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy totreatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study. EuroIntervention 5(2), 255-264 (2009).
28. Rubinstein A, Garcia Marti S, Souto A, Ferrante D, Augustovski F. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost Eff. Resour. Alloc. 7, 10 (2009).
29. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342(3), 145-153 (2000).
30. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group. Br. Med. J. (Clin. Res. Ed.) 297(6644), 319-328 (1988).
31. Murray CJ, Lauer JA, Hutubessy RC, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 361(9359), 717-725 (2003).
32. Rubinstein A, Colantonio L, Bardach A, et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health (In Press).
33. Bruni JM. Costos Directos de la Atención Médica de las Enfermedades Atribuibles al Consumo de Tabaco en Argentina. Ministerio de Salud y Ambiente de la Nación, Buenos Aires, Argentina (2005).
34. Lewison G. Beyond SCI citations -new ways to evaluate research. Curr. Sci. 89(9), 1524-1530 (2005).
35. Rubinstein A, Belizan M, Discacciati V. Are economic evaluations and health technology assessments increasingly demanded in times of rationing health services? The case of the Argentine financial crisis. Int. J. Technol. Assess. Health Care 23(2), 169-176 (2007).
36. Rubinstein A, Pichon-Riviere A, Augustovski F. Development and implementation of health technology assessment in Argentina: two steps forward and one step back. Int. J. Technol. Assess. Health Care 25(Suppl. 1), 260-269 (2009).
37. Resolución 674/03. Ministerio de Salud, Buenos Aires, Argentina (2003).
38. Augustovski F, Garay OU, Pichon Riviere A, Rubinstein A, Caporale JE. Economic evaluation guidelines in Latin America: a current snapshot. Expert Rev. Pharmacoecon. Outcomes Res. (2010) (In Press).
39. Supplementary Box 1 and Table 1 www.expert-reviews.com/toc/erp/10/4
40. Choosing Interventions that are Cost-Effective (WHO-CHOICE): country specific costs www.who.int/choice/country/en/index. html
41. UnitedHealth and NHLBI Collaborating Centers of Excellence www.nhlbi.nih.gov/about/globalhealth/ centers/index.htm
42. Southern cone of America Center of Excellence for Cardiovascular Health (SACECH). Spanish version www.iecs.org.ar/iecs-visor.php?cod-producto=432
43. Southern cone of America Center of Excellence for Cardiovascular Health (SACECH). English version www.iecs.org.ar/iecs-visor-institucional.php?cod- producto=433
44. Disease Control Priorities Project www.dcp2.org/pubs/dcp